Human CD20 / MS4A1 Protein (aa 213-297, His Tag)

B1,Bp35,CD20,CVID5,LEU-16,MS4A1,MS4A2,S7

• 100ug (NPP3678) Please inquiry

Catalog Number	P11007-H07H2
Organism Species	Human
Host	Human Cells
Synonyms	B1,Bp35,CD20,CVID5,LEU-16,MS4A1,MS4A2,S7
Molecular Weight	The recombinant human CD20 comprises 105 amino acids and has a predicted molecular mass of 12.1 kDa. The apparent molecular mass of the protein is approximately 23 kDa in SDS-PAGE under reducing conditions due to glycosylation.
predicted N	His
SDS-PAGE
Purity	> 83 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the human CD20 (NP_068769.2) (Glu213-Pro297) was expressed, with an N-terminal polyhistidine tag.
Bio-activity
Research Area	Immunology |Adaptive Immunity |B Cell |B Cell CD Antigen
Formulation	Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.
Reference	Tedder TF, et al. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 85(1): 208-12. Cragg MS, et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-74.. Polyak MJ, et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 17(7): 1384-9.